New antibody shows promise for severe asthma sufferers
NCT ID NCT06680947
First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests a new antibody drug (610) for adults with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. The goal is to see if adding this drug to standard treatment improves lung function and reduces asthma attacks over 52 weeks. 225 participants will receive either the drug or a placebo, and their breathing will be measured regularly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.